These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 35428250)

  • 21. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
    Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
    Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The COVID-19 Pandemic and the TRIPS Waiver: Patents and Flexibility.
    Lawson C; Rourke M
    J Law Med; 2022 Aug; 29(3):663-676. PubMed ID: 36056658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
    Kerry VB; Lee K
    Global Health; 2007 May; 3():3. PubMed ID: 17524147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program.
    Tenni B; Lexchin J; Akaleephan C; Kittitrakul C; Gleeson D
    Global Health; 2024 Jun; 20(1):46. PubMed ID: 38867208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement.
    Chaves GC; Oliveira MA
    Bull World Health Organ; 2007 Jan; 85(1):49-56. PubMed ID: 17242758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PATENTING OF MEDICINES IN UKRAINE THROUGH THE PRISM OF THE ASSOCIATION AGREEMENT WITH THE EU AND THE TRIPS AGREEMENT: IMPROVEMENT IN MEDICAL AND ADMINISTRATIVE REGULATIONS.
    Deshko L; Ivasyn O; Gurzhii T; Novikova T; Radyshevska O
    Georgian Med News; 2019 Mar; (288):154-158. PubMed ID: 31101796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes to intellectual property policy in South Africa: putting a stop to evergreening?
    Hill JE
    Expert Opin Ther Pat; 2014 Aug; 24(8):839-43. PubMed ID: 24965317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effects of Intellectual Property Rights on Access to Medicines and Catastrophic Expenditure.
    Jung Y; Kwon S
    Int J Health Serv; 2015; 45(3):507-29. PubMed ID: 26077858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.
    't Hoen EFM; Kujinga T; Boulet P
    J Pharm Policy Pract; 2018; 11():31. PubMed ID: 30524732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
    Townsend B
    Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.